source
- Ultragenyx's Angelman gene therapy fails Phase 3, company to cut expensesUltragenyx reported that its late‑stage Aspire trial of apazunersen in Angelman syndrome did not meet its primary or secondary endpoints. The primary goal of improving the Bayley‑4 cognitive raw sc…
- Superluminal Medicines raises $60 million to advance AI-designed MC4R drug for rare obesity formsSuperluminal Medicines, an AI-driven drug discovery startup, announced a $60 million financing round aimed at moving its first candidate toward clinical testing. The candidate targets the MC4R G p…